Ligand Pharmaceuticals (NASDAQ:LGND) Issues FY 2025 Earnings Guidance

Ligand Pharmaceuticals (NASDAQ:LGND) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 6.000-6.250 for the period, compared to the consensus earnings per share estimate of 6.140. The company issued revenue guidance of $180.0 million-$200.0 million, compared to the consensus revenue estimate of $188.8 million.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on LGND. Benchmark reissued a “buy” rating and issued a $135.00 price target on shares of Ligand Pharmaceuticals in a report on Monday, December 23rd. Barclays boosted their price target on Ligand Pharmaceuticals from $150.00 to $160.00 and gave the stock an “overweight” rating in a research note on Monday, December 16th. HC Wainwright reissued a “buy” rating on shares of Ligand Pharmaceuticals in a research report on Wednesday, December 11th. Royal Bank of Canada upped their target price on shares of Ligand Pharmaceuticals from $141.00 to $143.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. Finally, Oppenheimer raised their price objective on shares of Ligand Pharmaceuticals from $135.00 to $147.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Ligand Pharmaceuticals has a consensus rating of “Buy” and an average price target of $147.00.

Ligand Pharmaceuticals Trading Up 5.7 %

Shares of LGND opened at $122.23 on Friday. The company’s fifty day simple moving average is $114.03 and its 200 day simple moving average is $111.01. The company has a market cap of $2.31 billion, a price-to-earnings ratio of 48.70 and a beta of 1.04. Ligand Pharmaceuticals has a 1-year low of $67.72 and a 1-year high of $129.90.

Insiders Place Their Bets

In related news, CFO Octavio Espinoza sold 2,104 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $116.37, for a total value of $244,842.48. Following the completion of the transaction, the chief financial officer now owns 20,647 shares in the company, valued at $2,402,691.39. This trade represents a 9.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 5.90% of the company’s stock.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.